Iradimed Corporation's CEO, President and Chairman Roger E. Susi, via the Phillip Susi 2008 Dynasty Trust, completed the sale of 7,500 shares of the company's common stock on March 23 and 24, 2026, for aggregate proceeds of $752,609.
The transactions were carried out in multiple tranches at prices spanning $99.58 to $102.02 per share. On March 23, 2026, the trust sold 2,950 shares at a weighted average price of $99.58, 750 shares at $100.70, and 1,300 shares at $102.02. On March 24, 2026, it sold 1,585 shares at a weighted average price of $100.03 and 915 shares at $100.71.
These insider sales occurred while Iradimed's stock was trading close to its 52-week high of $107.90, a price level that reflects a 93% increase in the share price over the prior 12 months. Separately, the company's shares are trading at a price-to-earnings ratio of 58, a valuation that InvestingPro analysis characterizes as overvalued relative to its Fair Value.
Following the March transactions, ownership stakes tied to the Susi family remain substantial. The Phillip Susi 2008 Dynasty Trust now indirectly holds 2,232,500 shares of Iradimed common stock. In addition, the Roger E. Susi Revocable Trust holds 162,950 shares and the Matthew Susi 2008 Dynasty Trust holds 2,062,500 shares.
Market participants have had additional company-specific data to weigh. Iradimed reported fourth-quarter 2025 results that outperformed analyst expectations, with both earnings per share and revenue coming in ahead of forecasts. The better-than-expected quarter attracted attention from the investment community and coincided with notable stock price movement following the release.
Analysts continue to monitor Iradimed's trajectory in light of the quarter's results. The reporting notes that some firms have adjusted their outlooks based on the latest financial data, though no specific upgrades or downgrades were detailed in connection with these developments.
Context and implications
The sale by the Phillip Susi 2008 Dynasty Trust represents a modest liquidation relative to the family-linked holdings detailed above. The timing - sales executed when the stock is trading near a 52-week high - and the cited valuation signal from InvestingPro provide data points that investors and analysts can factor into their valuation and positioning decisions.
At the same time, the company's recent quarter, with revenue and EPS exceeding expectations, illustrates current operational momentum. Market reactions and analyst reassessments following earnings highlight ongoing scrutiny of Iradimed's near-term performance and valuation.
Key data points
- Insider sale: 7,500 shares sold by the Phillip Susi 2008 Dynasty Trust for $752,609 on March 23-24, 2026.
- Transaction prices: trades executed between $99.58 and $102.02 per share (details by tranche provided above).
- Post-sale holdings: Phillip Susi 2008 Dynasty Trust - 2,232,500 shares; Roger E. Susi Revocable Trust - 162,950 shares; Matthew Susi 2008 Dynasty Trust - 2,062,500 shares.
- Market context: shares trading near a 52-week high of $107.90 (a 93% gain over one year) and a P/E of 58, which InvestingPro considers overvalued relative to Fair Value.
- Recent results: Q4 2025 earnings and revenue exceeded analyst expectations.
Investor considerations
- Insider activity can inform sentiment analysis but does not on its own indicate a change in corporate fundamentals; the sale reduced the trust's holdings by 7,500 shares while substantial family-linked positions remain.
- Valuation metrics and third-party Fair Value assessments may influence investor views, particularly with a reported P/E of 58 and a recent InvestingPro determination of overvaluation.
- Recent earnings beats have prompted analyst attention and adjustments to outlooks, though the reporting did not specify which firms changed their ratings.
Note: The article reports the transactions, holdings, valuation notes, and quarterly results as described above. Specific analyst actions beyond the general observation that some firms have revised outlooks were not detailed in the information provided.